News | August 09, 2025
Akums reports Q1 FY26 PAT at Rs. 65 Cr
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Akums invested Rs. 272 crore in capital expenditure during FY25
The new combination therapy offers a dual mechanism of action for superior intraocular pressure control
Branded formulation business continues to perform well across domestic and export markets
Akums Drugs & Pharmaceuticals has launched Dapagliflozin + Pioglitazone tablets, a dual-action therapy for diabetes management
The facility is equipped with state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products
The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
Chobhe brings over 30 years of extensive experience in quality and regulatory management within the pharmaceutical industry
e brings over 27+ years of rich pharmaceutical experience
Subscribe To Our Newsletter & Stay Updated
